Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management
Open accessThe DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the most recently defined inflammatory demyelinating disease of the central nervous system (CNS). Over the last decade, several studies have helped delineate the characteristic clinical-MRI phenotypes of the disease, allowing distinction from aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) and multiple sclerosis (MS). The clinical manifestations of MOGAD are heterogeneous, ranging from isolated optic neuritis or myelitis to multifocal CNS demyelination often in the form of acute disseminated encephalomyelitis (ADEM), or cortical encephalitis. A relapsing course is observed in approximately 50% of patients. Characteristic MRI features have been described that increase the diagnostic suspicion (e.g., perineural optic nerve enhancement, spinal cord H-sign, T2-lesion resolution over time) and help discriminate from MS and AQP4+NMOSD, despite some overlap. The detection of MOG-IgG in the serum (and sometimes CSF) confirms the diagnosis in patients with compatible clinical-MRI phenotypes, but false positive results are occasionally encountered, especially with indiscriminate testing of large unselected populations. The type of cell-based assay used to evaluate for MOG-IgG (fixed vs. live) and antibody end-titer (low vs. high) can influence the likelihood of MOGAD diagnosis. International consensus diagnostic criteria for MOGAD are currently being compiled and will assist in clinical diagnosis and be useful for enrolment in clinical trials. Although randomized controlled trials are lacking, MOGAD acute attacks appear to be very responsive to high dose steroids and plasma exchange may be considered in refractory cases. Attack-prevention treatments also lack class-I data and empiric maintenance treatment is generally reserved for relapsing cases or patients with severe residual disability after the presenting attack. A variety of empiric steroid-sparing immunosuppressants can be considered and may be efficacious based on retrospective or prospective observational studies but prospective randomized placebo-controlled trials are needed to better guide treatment. In summary, this article will review our rapidly evolving understanding of MOGAD diagnosis and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Self-citationIgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
Self-citationThe spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Self-citationRuiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., Nakashima, I., Terzi, M., Totolyan, N., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 872
Self-citationDistinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Self-citationMOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1144-2 · Cited by 747
Clinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740
Howard, J. F., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., Murai, H., Bilinska, M., Shakarishvili, R., Smilowski, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00159-9 · Cited by 739
Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression
Pittock, S. J., Weinshenker, B. G., Lucchinetti, C. F., Wingerchuk, D. M., Corboy, J. R., & Lennon, V. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.964 · Cited by 701
Self-citationMyelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Quantifying axonal loss after optic neuritis with optical coherence tomography
Costello, F., Coupland, S., Hodge, W., Lorello, G. R., Koroluk, J., Pan, Y. I., Freedman, M. S., Zackon, D. H., & Kardon, R. H. (2006) · Annals of Neurology · doi:10.1002/ana.20851 · Cited by 610
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines
Filippi, M., Preziosa, P., Banwell, B. L., Barkhof, F., Ciccarelli, O., De Stefano, N., Geurts, J. J. G., Paul, F., Reich, D. S., Toosy, A. T., et al. (2019) · Brain · doi:10.1093/brain/awz144 · Cited by 560
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Self-citationClinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005560 · Cited by 538
Incidence and prevalence of multiple sclerosis in Europe: a systematic review
Kingwell, E., Marriott, J. J., Jetté, N., Pringsheim, T., Makhani, N., Morrow, S. A., Fisk, J. D., Evans, C., Béland, S. G., Kulaga, S., et al. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-128 · Cited by 520
Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis
Titulaer, M. J., Höftberger, R., Iizuka, T., Leypoldt, F., McCracken, L., Cellucci, T., Benson, L. A., Shu, H., Irioka, T., Hirano, M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24117 · Cited by 518
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O'Connor, K. C., McLaughlin, K. A., De Jager, P. L., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar-Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 416
López-Chiriboga, A. S., Majed, M., Fryer, J., Dubey, D., McKeon, A., Flanagan, E. P., Jitprapaikulsan, J., Kothapalli, N., Tillema, J.-M., Chen, J., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1814 · Cited by 410
Self-citationChen, J. J., Flanagan, E. P., Jitprapaikulsan, J., López-Chiriboga, A. (. S., Fryer, J. P., Leavitt, J. A., Weinshenker, B. G., McKeon, A., Tillema, J.-M., Lennon, V. A., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.07.020 · Cited by 408
Self-citationDobson, R., Ramagopalan, S., Davis, A., & Giovannoni, G. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304695 · Cited by 394
Dubey, D., Pittock, S. J., Krecke, K. N., Morris, P. P., Sechi, E., Zalewski, N. L., Weinshenker, B. G., Shosha, E., Lucchinetti, C. F., Fryer, J. P., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4053 · Cited by 384
Self-citationHöftberger, R., Guo, Y., Flanagan, E. P., Lopez-Chiriboga, A. S., Endmayr, V., Hochmeister, S., Joldic, D., Pittock, S. J., Tillema, J. M., Gorman, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02132-y · Cited by 369
Self-citationPrognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome
Hennes, E.-M., Baumann, M., Schanda, K., Anlar, B., Bajer-Kornek, B., Blaschek, A., Brantner-Inthaler, S., Diepold, K., Eisenkölbl, A., Gotwald, T., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004312 · Cited by 341
Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, E. P., Cabre, P., Weinshenker, B. G., Sauver, J. S., Jacobson, D. J., Majed, M., Lennon, V. A., Lucchinetti, C. F., McKeon, A., Matiello, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24617 · Cited by 338
Self-citationWaters, P., Fadda, G., Woodhall, M., O’Mahony, J., Brown, R. A., Castro, D. A., Longoni, G., Irani, S. R., Sun, B., Yeh, E. A., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2940 · Cited by 335
Self-citationArmangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., Sepulveda, M., Ruiz-Garcia, R., Muñoz-Batista, M., Ariño, H., González-Álvarez, V., Felipe-Rucián, A., Jesús Martínez-González, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30488-0 · Cited by 334
Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review
Papp, V., Magyari, M., Aktas, O., Berger, T., Broadley, S. A., Cabre, P., Jacob, A., Kira, J.-I., Leite, M. I., Marignier, R., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011153 · Cited by 310
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study
Takai, Y., Misu, T., Kaneko, K., Chihara, N., Narikawa, K., Tsuchida, S., Nishida, H., Komori, T., Seki, M., Komatsu, T., et al. (2020) · Brain · doi:10.1093/brain/awaa102 · Cited by 299
Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications
Popescu, B. F. G., Lennon, V. A., Parisi, J. E., Howe, C. L., Weigand, S. D., Cabrera-Gómez, J. A., Newell, K., Mandler, R. N., Pittock, S. J., Weinshenker, B. G., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318214332c · Cited by 296
Self-citationDamato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290
International multicenter examination of MOG antibody assays
Reindl, M., Schanda, K., Woodhall, M., Tea, F., Ramanathan, S., Sagen, J., Fryer, J. P., Mills, J., Teegen, B., Mindorf, S., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000674 · Cited by 284
Self-citationThe history of neuromyelitis optica
Jarius, S., & Wildemann, B. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-8 · Cited by 279
Cobo‐Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A. F., Maurey, H., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25909 · Cited by 270
Safety of intravenous immunoglobulin (IVIG) therapy
Katz, U., Achiron, A., Sherer, Y., & Shoenfeld, Y. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.08.011 · Cited by 265
Jurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., DeLuca, G., Chandratre, S., Leite, M. I., Vincent, A., et al. (2017) · Brain · doi:10.1093/brain/aww350 · Cited by 265
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
Maggi, P., Absinta, M., Grammatico, M., Vuolo, L., Emmi, G., Carlucci, G., Spagni, G., Barilaro, A., Repice, A. M., Emmi, L., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25146 · Cited by 245
A multicenter comparison of MOG-IgG cell-based assays
Waters, P. J., Komorowski, L., Woodhall, M., Lederer, S., Majed, M., Fryer, J., Mills, J., Flanagan, E. P., Irani, S. R., Kunchok, A. C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007096 · Cited by 241
Self-citationPositive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing
Sechi, E., Buciuc, M., Pittock, S. J., Chen, J. J., Fryer, J. P., Jenkins, S. M., Budhram, A., Weinshenker, B. G., Lopez-Chiriboga, A. S., Tillema, J.-M., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0912 · Cited by 234
Self-citationSteroid-sparing maintenance immunotherapy for MOG-IgG associated disorder
Chen, J. J., Flanagan, E. P., Bhatti, M. T., Jitprapaikulsan, J., Dubey, D., Lopez Chiriboga, A. (. S., Fryer, J. P., Weinshenker, B. G., McKeon, A., Tillema, J.-M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009758 · Cited by 233
Self-citationAntibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Kim, S.-M., Woodhall, M. R., Kim, J.-S., Kim, S.-J., Park, K. S., Vincent, A., Lee, K.-W., & Waters, P. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000163 · Cited by 232
Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
Stiebel-Kalish, H., Hellmann, M. A., Mimouni, M., Paul, F., Bialer, O., Bach, M., & Lotan, I. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000572 · Cited by 209
Kaneko, K., Sato, D. K., Nakashima, I., Ogawa, R., Akaishi, T., Takai, Y., Nishiyama, S., Takahashi, T., Misu, T., Kuroda, H., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-317969 · Cited by 203
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
Whittam, D. H., Cobo-Calvo, A., Lopez-Chiriboga, A. S., Pardo, S., Gornall, M., Cicconi, S., Brandt, A., Berek, K., Berger, T., Jelcic, I., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102251 · Cited by 184
Self-citationNeurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes
Sechi, E., Markovic, S. N., McKeon, A. B., Dubey, D., Liewluck, T., Lennon, V. A., Lopez-Chiriboga, A. S., Klein, C. J., Mauermann, M. L., Pittock, S. J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010632 · Cited by 182
Self-citationAnti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort
Ketelslegers, I. A., Van Pelt, D. E., Bryde, S., Neuteboom, R. F., Catsman-Berrevoets, C. E., Hamann, D., & Hintzen, R. Q. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514566666 · Cited by 179
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
Spadaro, M., Gerdes, L. A., Mayer, M. C., Ertl-Wagner, B., Laurent, S., Krumbholz, M., Breithaupt, C., Högen, T., Straube, A., Giese, A., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.164 · Cited by 176
Durozard, P., Rico, A., Boutiere, C., Maarouf, A., Lacroix, R., Cointe, S., Fritz, S., Brunet, C., Pelletier, J., Marignier, R., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25648 · Cited by 168
Jarius, S., Pellkofer, H., Siebert, N., Korporal-Kuhnke, M., Hümmert, M. W., Ringelstein, M., Rommer, P. S., Ayzenberg, I., Ruprecht, K., Klotz, L., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01824-2 · Cited by 168
Mariotto, S., Ferrari, S., Monaco, S., Benedetti, M. D., Schanda, K., Alberti, D., Farinazzo, A., Capra, R., Mancinelli, C., De Rossi, N., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8635-4 · Cited by 165
Self-citationTreatment of MOG antibody associated disorders: results of an international survey
Whittam, D. H., Karthikeayan, V., Gibbons, E., Kneen, R., Chandratre, S., Ciccarelli, O., Hacohen, Y., Seze, J. D., Deiva, K., Hintzen, R. Q., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10026-y · Cited by 164
Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders
Sechi, E., Krecke, K. N., Messina, S. A., Buciuc, M., Pittock, S. J., Chen, J. J., Weinshenker, B. G., Lopez-Chiriboga, A. S., Lucchinetti, C. F., Zalewski, N. L., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012467 · Cited by 162
Self-citationRingelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Gahlen, A., Novi, G., Hayward-Könnecke, H., Schippling, S., Rommer, P. S., Kornek, B., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001100 · Cited by 160
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects
Lampasona, V., Franciotta, D. M., Furlan, R., Zanaboni, S., Fazio, R., Bonifacio, E. E., Comı, G., & Martino, G. (2004) · Neurology · doi:10.1212/01.wnl.0000127615.15768.ae · Cited by 157
Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS
Banks, S. A., Morris, P. P., Chen, J. J.-W., Pittock, S. J., Sechi, E., Kunchok, A. C., Tillema, J., Fryer, J. P., Weinshenker, B. G., Krecke, K. N., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325121 · Cited by 153
Self-citationLebar, R., Lubetzki, C., Vincent, C., Lombrail, P., & Boutry, J. M. (1986) · PubMed Central · Cited by 151
Kunchok, A. C., Aksamit, A. J., Davis, J. M., Kantarci, O. H., Keegan, B. M., Pittock, S. J., Weinshenker, B. G., & McKeon, A. B. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1162 · Cited by 151
Self-citationKim, S., Go, M. J., Sung, J., Park, K. S., & Lee, K. W. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.112 · Cited by 143
Akaishi, T., Sato, D. K., Nakashima, I., Takeshita, T., Takahashi, T., Doi, H., Kurosawa, K., Kaneko, K., Kuroda, H., Nishiyama, S., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310206 · Cited by 141
Central canal enhancement and the trident sign in spinal cord sarcoidosis
Zalewski, N. L., Krecke, K. N., Weinshenker, B. G., Aksamit, A. J., Conway, B. L., McKeon, A. B., & Flanagan, E. P. (2016) · Neurology · doi:10.1212/wnl.0000000000002992 · Cited by 134
Self-citationHacohen, Y., Rossor, T. E., Mankad, K., Chong, W. K., Lux, A. L., Wassmer, E., Lim, M. J., Barkhof, F., Ciccarelli, O., & Hemingway, C. A. (2017) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.13649 · Cited by 127
Lee, H., Kim, B., Waters, P. J., Woodhall, M. R., Irani, S. R., Ahn, S., Kim, S.-J., & Kim, S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1335-x · Cited by 122
Filippatou, A. G., Mukharesh, L., Saidha, S., Calabresi, P. A., & Sotirchos, E. S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.540156 · Cited by 121
Fadda, G., Armangué, T., Hacohen, Y., Chitnis, T., & Banwell, B. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30432-4 · Cited by 119
Self-citationJarius, S., Metz, I., König, F. B., Ruprecht, K., Reindl, M., Paul, F., Brück, W., & Wildemann, B. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515622986 · Cited by 116
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases
Mariotto, S., Gajofatto, A., Batzu, L., Delogu, R., Sechi, G., Leoni, S., Pirastru, M. I., Bonetti, B., Zanoni, M., Alberti, D., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008479 · Cited by 116
Self-citationKwon, Y. N., Kim, B., Kim, J.-S., Mo, H., Choi, K., Oh, S., Kim, J.-E., Nam, T.-S., Sohn, E. H., Heo, S. H., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001095 · Cited by 116
Flanagan, E. P. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000742 · Cited by 115
Self-citationHassan, M. B., Stern, C., Flanagan, E. P., Pittock, S. J., Kunchok, A. C., Foster, R. C., Jitprapaikulsan, J., Hodge, D. O., Bhatti, M. T., & Chen, J. J.-W. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.014 · Cited by 106
Self-citationSerious safety events in rituximab‐treated multiple sclerosis and related disorders
Vollmer, B. L., Wallach, A. I., Corboy, J. R., Dubovskaya, K., Álvarez, E., & Kister, I. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51136 · Cited by 106
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders
Rinaldi, S., Davies, A. J., Fehmi, J., Beadnall, H. N., Wang, J., Hardy, T. A., Barnett, M. H., Broadley, S., Waters, P. J., Reddel, S., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000924 · Cited by 106
Primary Angiitis of the Central Nervous System
Boulouis, G., de BOYSSON, H., Zuber, M., Guillevin, L., Méary, E., Costalat, V., Pagnoux, C., & Naggara, O. N. (2017) · Stroke · doi:10.1161/strokeaha.116.016194 · Cited by 104
Brain and cord imaging features in neuromyelitis optica spectrum disorders
Cacciaguerra, L., Meani, A., Mesaroš, Š., Radaelli, M., Palace, J. A., Dujmović, I., Pagani, E., Martinelli, V., Matthews, L., Drulovic, J. S., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25411 · Cited by 103
Self-citationMariano, R., Messina, S., Kumar, K. A., Küker, W., Leite, M. I., & Palace, J. A. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12732 · Cited by 103
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease
Kim, H., Lee, E., Kim, S., Choi, L., Kim, K., Kim, H. W., Kim, K., & Lim, Y. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000708 · Cited by 103
Chen, J. J., Sotirchos, E. S., Henderson, A. D., Vasileiou, E. S., Flanagan, E. P., Bhatti, M. T., Jamali, S., Eggenberger, E. R., Dinome, M., Frohman, L. P., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103525 · Cited by 102
Self-citationZhou, L., Huang, Y., Li, H., Fan, J., ZhangBao, J., Yu, H., Li, Y., Lu, J., Zhao, C., Lü, C., et al. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.01.007 · Cited by 100
Sotirchos, E. S., Filippatou, A., Fitzgerald, K. C., Salama, S., Pardo, S., Wang, J., Ogbuokiri, E., Cowley, N. J., Pellegrini, N., Murphy, O. C., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519864928 · Cited by 98 · cited 2×
“The cause of the discrepancy between the detected structural abnormalities and different functional impairment in the two diseases remains unclear, and has been speculated to be related to the pathophysiology of AQP4IgG+NMOSD being an astrocytopathy with potential for more severe retinal dysfunction (135).”
BackgroundResultElsbernd, P. M., Hoffman, W. R., Carter, J. L., & Wingerchuk, D. M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102696 · Cited by 96
Jarius, S., Lechner, C., Wendel, E. M., Baumann, M., Breu, M., Schimmel, M., Karenfort, M., Marina, A. D., Merkenschlager, A., Thiels, C., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01825-1 · Cited by 94
Incidence of multiple sclerosis in China: A nationwide hospital-based study
Tian, D., Zhang, C., Yuan, M., Yang, X., Gu, H., Li, Z., Wang, Y., & Shi, F. (2020) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2020.100010 · Cited by 93
Akaishi, T., Takahashi, T., Misu, T., Kaneko, K., Takai, Y., Nishiyama, S., Ogawa, R., Fujimori, J., Ishii, T., Aoki, M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012175 · Cited by 93
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology
Pauli, F. D., Höftberger, R., Reindl, M., Beer, R., Rhomberg, P., Schanda, K., Sato, D. K., Fujihara, K., Lassmann, H., Schmutzhard, E., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000175 · Cited by 91
Ayzenberg, I., Richter, D., Henke, E., Asseyer, S., Paul, F., Trebst, C., Hümmert, M. W., Havla, J. B., Kümpfel, T., Ringelstein, M., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000985 · Cited by 90
Tian, D., Li, Z., Yuan, M., Zhang, C., Gu, H., Wang, Y., & Shi, F. (2020) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2020.100021 · Cited by 89
Camera, V., Holm-Mercer, L., Ali, A. A. H., Messina, S., Horvat, T., Küker, W., Leite, M. I., & Palace, J. A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37833 · Cited by 89
Monitoring B-cell repopulation after depletion therapy in neurologic patients
Ellwardt, E., Ellwardt, L., Bittner, S., & Zipp, F. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000463 · Cited by 85
Chang, X., Huang, W., Wang, L., ZhangBao, J., Zhou, L., Lü, C., Wang, M., Yu, J. Y., Li, H., Li, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647618 · Cited by 84
Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders
Zalewski, N. L., Morris, P. P., Weinshenker, B. G., Lucchinetti, C. F., Guo, Y. X., Pittock, S. J., Krecke, K. N., Kaufmann, T. J., Wingerchuk, D. M., Kumar, N., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314738 · Cited by 83
Self-citationde Oliveira, L. M., Apóstolos‐Pereira, S. L., Pitombeira, M. S., Torretta, P. H. B., Callegaro, D., & Sato, D. K. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518811597 · Cited by 83
Complications of Plasma Exchange in Neurological Patients
Rodnitzky, R. L., & Goeken, J. A. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510180028007 · Cited by 81
Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis
Mariano, R., Messina, S., Roca‐Fernández, A., Leite, M. I., Kong, Y., & Palace, J. A. (2020) · Brain · doi:10.1093/brain/awaa347 · Cited by 79
Sechi, E., & Flanagan, E. P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.673339 · Cited by 79
Self-citationProdromal headache in MOG-antibody positive optic neuritis
Asseyer, S., Hamblin, J., Messina, S., Mariano, R., Siebert, N., Everett, R., Küker, W., Bellmann–Strobl, J., Ruprecht, K., Jarius, S., et al. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.101965 · Cited by 77
Cranial nerve involvement in patients with MOG antibody–associated disease
Cobo‐Calvo, Á., Ayrignac, X., Kerschen, P., Horellou, P., Cotton, F., Labauge, P. M., Vukusic, S., Deiva, K., Serguera, C., & Marignier, R. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000543 · Cited by 75
Clinical and neuroimaging findings in MOGAD–MRI and OCT
Bartels, F., Lu, A., Oertel, F. C., Finke, C., Paul, F., & Chien, C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13641 · Cited by 75
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults
The OFSEP Group, Cobo‐Calvo, Á., The REEM Group, Sepúlveda, M., d’Indy, H., Armangué, T., Ruiz, A., Maillart, É., Papeix, C., Audoin, B., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-018-9160-9 · Cited by 71
The temporal evolution of structural and functional measures after acute optic neuritis
Costello, F., Pan, Y., Yeh, E. A., Hodge, W., Burton, J., & Kardon, R. H. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309704 · Cited by 69
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
Graf, J., Mareš, J., Barnett, M. H., Aktaş, O., Albrecht, P., Zamvil, S. S., & Hartung, H. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000918 · Cited by 69
Oertel, F. C., Outteryck, O., Knier, B., Zimmermann, H. G., Borisow, N., Bellmann–Strobl, J., Blaschek, A., Jarius, S., Reindl, M., Ruprecht, K., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1521-5 · Cited by 68
MOG antibodies in combined central and peripheral demyelination syndromes
Campo, R. V. D., Stephens, A., Collazo, I. V. M., & Rubin, D. I. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000503 · Cited by 67
Duan, Y., Zhuo, Z., Li, H., Tian, D., Li, Y., Yang, L., Gao, C., Zhang, T., Zhang, X., Shi, F., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-324826 · Cited by 67
Messina, S., Mariano, R., Roca‐Fernández, A., Cavey, A., Juryńczyk, M., Leite, M. I., Calabrese, M., Jenkinson, M., & Palace, J. A. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211018987 · Cited by 67
Silent New Brain MRI Lesions in Children with MOG‐Antibody Associated Disease
Fadda, G., Banwell, B., Waters, P. J., Marrie, R. A., Yeh, E. A., O’Mahony, J., Arnold, D. L., Bar‐Or, A., & the Canadian Pediatric Demyelinating Disease Network (2020) · Annals of Neurology · doi:10.1002/ana.25957 · Cited by 62
Self-citationComplement Activation Is a Prominent Feature of MOGAD
Keller, C. W., Lopez, J. A., Wendel, E., Ramanathan, S., Groß, C. C., Klotz, L., Reindl, M., Dale, R. C., Wiendl, H., Rostasy, K. M., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26226 · Cited by 62
Fadda, G., Alves, C., O’Mahony, J., Castro, D. A., Yeh, E. A., Marrie, R. A., Arnold, D. L., Waters, P. J., Bar‐Or, A., Vossough, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28871 · Cited by 59
Self-citationNeurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders
Mariotto, S., Ferrari, S., Gastaldi, M., Franciotta, D. M., Sechi, E., Capra, R., Mancinelli, C. R., Schanda, K., Alberti, D., Orlandi, R., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320287 · Cited by 56
Self-citationMOG-IgG1 and co-existence of neuronal autoantibodies
Kunchok, A. C., Flanagan, E. P., Krecke, K. N., Chen, J. J.-W., Caceres, J., Dominick, J., Ferguson, I., Kinkel, R. P., Probasco, J. C., Ruvalcaba, M., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520951046 · Cited by 56
Self-citationThe long‐term outcome of MOGAD: An observational national cohort study of 61 patients
Deschamps, R., Pique, J., Ayrignac, X., Collongues, N., Audoin, B., Zéphir, H., Ciron, J., Cohen, M., Aboab, J., Mathey, G., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14746 · Cited by 55
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Redenbaugh, V., Montalvo, M., Sechi, E., Buciuc, M., Fryer, J. P., McKeon, A. B., Lennon, V. A., Mills, J. R., Weinshenker, B. G., Wingerchuk, D. M., et al. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211052656 · Cited by 54
Self-citationTargeting B cells to modify MS, NMOSD, and MOGAD: Part 2
Graf, J., Mareš, J., Barnett, M. H., Aktaş, O., Albrecht, P., Zamvil, S. S., & Hartung, H.-P. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000919 · Cited by 53
Zhao-Fleming, H. H., Sánchez, C. V., Sechi, E., Inbarasu, J. D., Wijdicks, E. F. M., Pittock, S. J., Chen, J. J.-W., Wingerchuk, D. M., Weinshenker, B. G., Lopez-Chiriboga, A. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012599 · Cited by 53
Self-citationHeld, F., Kalluri, S. R., Berthele, A., Klein, A.-K., Reindl, M., & Hemmer, B. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211022767 · Cited by 51
Lebrun‐Frénay, C., Cohen, M., Rosenthal‐Allieri, M. A., Bresch, S., Benzaken, S., Marignier, R., Seitz‐Polski, B., & Ticchioni, M. (2018) · Neurology and Therapy · doi:10.1007/s40120-018-0101-4 · Cited by 46
Kunchok, A. C., Krecke, K. N., Flanagan, E. P., Jitprapaikulsan, J., Lopez-Chiriboga, A. S., Chen, J. J.-W., Weinshenker, B. G., & Pittock, S. J. (2019) · Neurology · doi:10.1212/wnl.0000000000008786 · Cited by 45
Self-citationPregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Collongues, N., Rego, C. A. D., Bourre, B., Biotti, D., Marignier, R., SILVA, A. C. F. D., Santos, E., Maillart, É., Papeix, C., Palace, J. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011744 · Cited by 45
Ciotti, J. R., Eby, N. S., Brier, M. R., Wu, G. F., Chahin, S., Cross, A. H., & Naismith, R. T. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211007086 · Cited by 45
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder
Tajfirouz, D. A., Padungkiatsagul, T., Beres, S., Moss, H. E., Pittock, S. J., Flanagan, E. P., Kunchok, A. C., Shah, S., Bhatti, M. T., & Chen, J. J.-W. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211011450 · Cited by 45
Self-citationLotan, I., Romanow, G., & Levy, M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103189 · Cited by 44
Martínez‐Lapiscina, E. H., Sepúlveda, M., Torres–Torres, R., Albà-Arbalat, S., Llufriú, S., Blanco, Y., Guerrero-Zamora, A. M., Solà‐Valls, N., Ortiz-Pérez, S., Villoslada, P., et al. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616655264 · Cited by 43
Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology
Sechi, E., Shosha, E., Williams, J., Pittock, S. J., Weinshenker, B. G., Keegan, B. M., Zalewski, N. L., Lopez-Chiriboga, A. S., Jitprapaikulsan, J., & Flanagan, E. P. (2019) · Neurology · doi:10.1212/wnl.0000000000007828 · Cited by 40
Self-citationPain, depression, and quality of life in adults with MOG‐antibody–associated disease
Asseyer, S., Henke, E., Trebst, C., Hümmert, M. W., Wildemann, B., Jarius, S., Ringelstein, M., Aktaş, O., Pawlitzki, M., Korsen, M., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.14729 · Cited by 40
Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions
Mustafa, R., Passe, T. J., Lopez-Chiriboga, A. S., Weinshenker, B. G., Krecke, K. N., Zalewski, N. L., Diehn, F. E., Sechi, E., Mandrekar, J. N., Kaufmann, T. J., et al. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001036 · Cited by 40
Self-citationSechi, E., Buciuc, M., Flanagan, E. P., Pittock, S. J., Banks, S. A., Lopez-Chiriboga, A. S., Bhatti, M. T., & Chen, J. J.-W. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102638 · Cited by 39
Self-citationC3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
Pache, F. C., Ringelstein, M., Aktaş, O., Kleiter, I., Jarius, S., Siebert, N., Bellmann–Strobl, J., Paul, F., & Ruprecht, K. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577699 · Cited by 35
Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease
Akaishi, T., Himori, N., Takeshita, T., Misu, T., Takahashi, T., Takai, Y., Nishiyama, S., Fujimori, J., Ishii, T., Aoki, M., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103222 · Cited by 34
Epstein, S. E., Levin, S. N., Onomichi, K. B., Langston, C., Yeshokumar, A. K., Fabian, M. T., Sand, I. K., Klineova, S., LUBLIN, F. D., Dykstra, K., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103229 · Cited by 33
Guerra, H., Pittock, S. J., Moder, K. G., Fryer, J. P., Gadoth, A., & Flanagan, E. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.02.006 · Cited by 32
Self-citationContentti, E. C., López, P. A., Pettinicchi, J. P., Pappolla, A., Míguez, J., Patrucco, L., Cristiano, E., Vrech, C., Tkachuk, V. A., Liwacki, S., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102742 · Cited by 32
Hofer, L., Mariotto, S., Wurth, S., Ferrari, S., Mancinelli, C. R., Delogu, R., Monaco, S., Gajofatto, A., Schwaiger, C., Rostasy, K. M., et al. (2019) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217319848463 · Cited by 31
Self-citationNfL levels predominantly increase at disease onset in MOG-Abs-associated disorders
Mariotto, S., Gastaldi, M., Grazian, L., Mancinelli, C. R., Capra, R., Marignier, R., Alberti, D., Zanzoni, S., Schanda, K., Franciotta, D. M., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102833 · Cited by 31
Self-citationFrequent retinal ganglion cell damage after acute optic neuritis
Brandt, A. U., Specovius, S., Oberwahrenbrock, T., Zimmermann, H. G., Paul, F., & Costello, F. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.04.006 · Cited by 29
Papathanasiou, A., Tănăsescu, R., Davis, J., Rocha, M. F., Singhal, S., O’Donoghue, M., & Constantinescu, C. S. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09586-5 · Cited by 29
Nan, D., Zhang, Y., Han, J., & Jin, T. (2021) · Neurological Sciences · doi:10.1007/s10072-020-04942-0 · Cited by 29
MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis
Wildemann, B., Jarius, S., Franz, J., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02236-5 · Cited by 28
Fabri, T. L., O’Mahony, J., Fadda, G., Gur, R. E., Gur, R. C., Yeh, E. A., Banwell, B., & Till, C. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103689 · Cited by 28
Self-citationWang, J., Qiu, Z., Li, D., Yang, X., Ding, Y., Gao, L., Liu, A., Yang, S., Li, C., Gao, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722404 · Cited by 27
Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies
Sechi, E., & Ζεκερίδου, Α. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.005 · Cited by 26
Self-citationHigh incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018
Willumsen, J. S., Aarseth, J. H., Myhr, K.-M., & Midgard, R. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000713 · Cited by 24 · cited 1×
“3/million) (41, 43), and markedly lower than that of MS (7–144/million) (42, 44), accepting a wide geographical variability.”
BackgroundMOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome
Mariotto, S., Monaco, S., Peschl, P., Coledan, I., Mazzi, R., Höftberger, R., Reindl, M., & Ferrari, S. (2017) · BMC Neurology · doi:10.1186/s12883-017-0971-6 · Cited by 24
Self-citationAlvarenga, R. M. P., Neri, V. C., Araújo, A. C. R. D. A. E., da Silva, E. B., Alvarenga, M. P., Pereira, A. B. C. N. D. G., Brandão, A. C., Alvarenga-Filho, H., Guimarães, M. P. M., Marignier, R., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.07.026 · Cited by 24
Deschamps, R., Philibert, M., Lamirel, C., Lambert, J., Vasseur, V., Guéguen, A., Bensa, C., Lecler, A., Marignier, R., Vignal‐Clermont, C., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520937281 · Cited by 23
da Costa, M. D., Rato, M. L., Cruz, D., Valadas, A., Antunes, A. P., & Albuquerque, L. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577739 · Cited by 23
Serum neurofilament light chain studies in neurological disorders, hints for interpretation
Mariotto, S., Sechi, E., & Ferrari, S. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116986 · Cited by 22
Self-citationLai, Q., Zhang, Y., Cai, M., Zheng, Y., Qiao, S., Fang, G., & Shen, C.-H. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211054157 · Cited by 22
Newsome, S. D., Cross, A. H., Fox, R. J., Halper, J., Kanellis, P., Bebo, B. F., Li, D., Cutter, G., Rammohan, K. W., & Salter, A. R. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001057 · Cited by 21
Evaluation and Management of Acute Myelopathy
Sechi, E., & Flanagan, E. P. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1733792 · Cited by 21
Self-citationSechi, E., Addis, A., Batzu, L., Mariotto, S., Ferrari, S., Conti, M., & Sechi, G. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517721661 · Cited by 19
Self-citationContentti, E. C., López, P. A., Criniti, J. M., Pettinicchi, J. P., Cristiano, E., Patrucco, L., Contreras, E. B., Gómez‐Figueroa, E., Flores-Rivera, J. D. J., Díaz, E. P. C., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15178 · Cited by 19
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Januel, É., Seze, J. D., Vermersch, P., Maillart, É., Bourre, B., Pique, J., Moisset, X., Bensa, C., Maarouf, A., Pelletier, J., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211049737 · Cited by 18
Sechi, E., Mariotto, S., McKeon, A. B., Krecke, K. N., Pittock, S. J., Ferrari, S., Monaco, S., Flanagan, E. P., Zanzoni, S., Rabinstein, A. A., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031482 · Cited by 16
Self-citationWang, M., Zeng, P., Chen, D., Xue, H., Cui, Z., Zhang, H., Jia, D., & Zhang, C. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103035 · Cited by 16
Bock, H. L., Juretzek, T., Handreka, R., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103554 · Cited by 15
GABA A receptor autoimmunity after alemtuzumab treatment for multiple sclerosis
Maniscalco, G. T., Mariotto, S., Höftberger, R., Capra, R., Servillo, G., Manzo, V., Napolitano, M., Candelaresi, P., Gerevini, S., Ferrari, S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010310 · Cited by 13
Self-citationThe use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
Roca-Fernández, A., Camera, V, Loncarevic-Whitaker, G., Messina, S., Mariano, R., Vincent, A., Sharma, S., Leite, M., & Palace, J. (2021) · Multiple Sclerosis Journal - Experimental, Translational and Clinical · doi:10.1177/20552173211066446 · Cited by 12
Zara, P., Floris, V., Flanagan, E. P., Lopez-Chiriboga, A. S., Weinshenker, B. G., Solla, P., & Sechi, E. (2021) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173211048761 · Cited by 9
Self-citation
Metadata
- Authors
- Sechi, E., Cacciaguerra, L., Chen, J. J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2022-06-17
- Volume
- 13
- Pages
- 885218-885218
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W4283071210
- Cited by
- 325
- References
- 164
- FWCI
- 35.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.